EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — Trials · CancerIndex

Clinical trials

Registered studies

20 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 13
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 15%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–17 of 17 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03984448	Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas	active not recruiting	Phase 2 / Phase 3	363	National Cancer Institute (NCI)NIH	1	Aug 4, 2026	clinicaltrials
NCT04799275	Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma	active not recruiting	Phase 2 / Phase 3	422	National Cancer Institute (NCI)NIH	1	Jul 8, 2026